Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dexamethasone sodium phosphate
Drug ID BADD_D00625
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Marketing Status Prescription; Discontinued
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00975
MeSH ID C004180
PubChem ID 16961
TTD Drug ID D0NA8U
NDC Product Code 67457-423; 68083-474; 67457-418; 0404-9841; 71872-7205; 68083-473; 52584-239; 70121-1452; 50090-0627; 60722-3014; 0641-6145; 70069-025; 51662-1432; 72572-122; 53225-3660; 71872-7147; 51927-0135; 71872-7021; 71872-7128; 0641-6146; 67457-484; 24208-720; 71872-7157; 70529-118; 71872-7092; 55150-304; 0404-9843; 50090-3541; 52584-421; 67457-421; 70518-3379; 51662-1391; 55150-305; 70069-024; 63323-506; 51662-1370; 49452-2473; 50090-3300; 55150-239; 70121-1451; 55150-238; 76420-077; 0395-8141; 67457-420; 71872-7171; 51662-1343; 24002-0025; 70069-022; 55154-9364; 55150-237; 67457-483; 71872-7164; 70121-1450; 67457-419; 72572-120; 71872-7091; 71872-7153; 79572-013; 52128-159; 70518-2936; 52584-420; 0641-0367; 63323-165; 50090-2313; 52584-422; 50090-4567; 70069-023; 71872-7239; 76420-185; 51927-1430; 65089-0001; 55154-8338; 0404-9842; 70518-3119; 67457-422; 0009-5027; 76045-106; 76045-109; 51662-1297; 70518-3019; 51552-0025; 76420-270; 70529-112; 38779-0071; 76045-210; 55154-5118; 70518-0532; 81565-202; 49452-2470; 57582-015; 70529-045; 63323-516; 70518-0410; 70121-1399; 70069-021; 82298-113
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H28FNa2O8P
CAS Registry Number 2392-39-4
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+ ]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Cushingoid05.01.01.002; 14.11.01.006; 19.07.03.001; 24.08.02.004--
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Erythema23.03.06.001--Not Available
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Glaucoma06.03.01.002--
Headache17.14.01.001--
Hiccups07.01.06.009; 22.02.04.002--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypokalaemic syndrome14.05.03.003--Not Available
Hypothalamo-pituitary disorder05.03.04.003--Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Increased insulin requirement05.06.01.006; 14.06.01.006--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Large intestine perforation07.04.06.005; 12.02.03.005--
The 1th Page    1 2 3    Next   Last    Total 3 Pages